Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Peeters, M.
Raoul, J.-L.
Van Laethem, J.-L.
Rougier, P.
Brezault, C.
Husseini, F.
Cals, L.
Zubel, A.
Vedovato, J.-C.
机构：
[1] State Univ Ghent Hosp, Dept Gastroenterol Hepatol, B-9000 Ghent, Belgium
[2] Ctr E Marquis, Rennes, France
[3] Free Univ Brussels, Erasme Hosp, B-1050 Brussels, Belgium
[4] Hop Ambroise Pare, Boulogne, France
[5] Hop Cochin, F-75674 Paris, France
[6] Hop Louis Pasteur, Colmar, France
[7] Hop Font Pre, Toulon, France
[8] Merck KGaA, Darmstadt, Germany
[9] Merck Lipha Sante, Paris, France
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [1] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.
    Smith, D. M.
    Legoux, J.
    Brunet, R.
    Adhoute, X.
    Blanc, J.
    Fonck, M.
    Vendrely, V.
    Becouarn, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [2] FIRST LINE CHEMOTHERAPY (FLC) USING IRINOTECAN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFIRI) COMBINED WITH BEVACIZUMAB IN MEATASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 62 - 62
  • [3] Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)
    Folprecht, G.
    Lutz, M. P.
    Schoeffski, P.
    Seufferlein, T.
    Nolting, A.
    Pollert, P.
    Koehne, C.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 199
  • [4] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
    Andric, Z.
    Murtezani, Z.
    Kovcin, V
    Gutovic, J.
    Kostic, S.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
  • [5] PHASE II STUDY OF FIRST-LINE SUNITINIB (SU) IN COMBINATION WITH IRINOTECAN, LEUCOVORIN, AND 5-FLUOROURACIL (5-FU) (FOLFIRI) IN JAPANESE PATIENTS (PTS) WITH UNRESECTABLE/METASTATIC COLORECTAL CANCER (MCRC)
    Tsuji, A.
    Denda, T.
    Tsuji, Y.
    Satoh, T.
    Yoshida, M.
    Nishina, Y.
    Nagase, M.
    Komatsu, Y.
    Kato, T.
    Muro, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 199 - 200
  • [6] Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer
    Trarbach, T.
    Schuette, K.
    Stoehlmacher, J.
    Goekkurt, E.
    Guenther, H.
    Ubbelohde, U.
    Stroszczynski, C.
    Ehninger, G.
    Folprecht, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Biweekly administration of irinotecan (CPT-11), oxaliplatin (OX) and 5-fluorouracil (5-FU) as first-line treatment of advanced or metastatic colorectal cancer (MCRC)
    Reina, JJ
    Sánchez-Rovira, P
    Bernabé, R
    Bolaños, M
    González, E
    Belón, J
    Gómez-Reina, MJ
    Gallurt, P
    Moreno-Nogueira, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 260S - 260S
  • [8] FIRST LINE CHEMOTHERAPY (FLC) USING OXALIPLATIN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFOX-4) COMBINED WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Man, S.
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 66 - 66
  • [9] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    S Falk
    D Jackson
    [J]. British Journal of Cancer, 2002, 86 : 1677 - 1683
  • [10] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345